"Interferon Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA).
| Descriptor ID |
D007370
|
| MeSH Number(s) |
D12.644.276.374.440.890 D12.776.467.374.440.890 D23.529.374.440.890
|
| Concept/Terms |
Interferon Type I- Interferon Type I
- Type I Interferons
- Interferons, Type I
- Interferons Type I
- Type I Interferon
- Interferon, Type I
|
Below are MeSH descriptors whose meaning is more general than "Interferon Type I".
Below are MeSH descriptors whose meaning is more specific than "Interferon Type I".
This graph shows the total number of publications written about "Interferon Type I" by people in this website by year, and whether "Interferon Type I" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 0 | 3 |
| 1996 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 4 | 1 | 5 |
| 2011 | 1 | 0 | 1 |
| 2012 | 3 | 0 | 3 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 3 | 0 | 3 |
| 2016 | 2 | 2 | 4 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 4 | 5 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 2 | 3 |
| 2022 | 3 | 0 | 3 |
| 2023 | 5 | 1 | 6 |
| 2024 | 1 | 1 | 2 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon Type I" by people in Profiles.
-
Type I interferon limits central nervous system autoimmunity by modulating the microRNA-21-FOXO1 axis in pathogenic T helper 17 cells. Sci Transl Med. 2025 Sep 10; 17(815):eadp5802.
-
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy. Nature. 2025 Oct; 646(8084):462-473.
-
Loss of ARID1A 'loops' in STING. Trends Immunol. 2024 08; 45(8):568-570.
-
Identification of Nonfunctional Alternatively Spliced Isoforms of STING in Human Acute Myeloid Leukemia. Cancer Res Commun. 2024 03 25; 4(3):911-918.
-
STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response. Leukemia. 2024 May; 38(5):1143-1155.
-
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity. Nat Cancer. 2024 04; 5(4):601-624.
-
Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer. JCI Insight. 2024 02 20; 9(6).
-
Type I interferons, inflammation, and fatigue in a longitudinal RNA study of women with breast cancer. Brain Behav Immun. 2024 May; 118:312-317.
-
Autoantibodies against type I IFNs in humans with alternative NF-?B pathway deficiency. Nature. 2023 11; 623(7988):803-813.
-
Blockade of interferon signaling decreases gut barrier integrity and promotes severe West Nile virus disease. Nat Commun. 2023 09 25; 14(1):5973.